Retension Pharmaceuticals, Inc. RTSN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 2.43M | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 12.56M | -- | -- | -- | |
| Operating Income | -12.56M | -- | -- | -- | |
| Income Before Tax | -11.94M | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -11.94 | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -11.94M | -- | -- | -- | |
| EBIT | -12.56M | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -14.81 | -- | -- | -- | |
| Normalized Basic EPS | -9.26 | -- | -- | -- | |
| EPS Diluted | -14.81 | -- | -- | -- | |
| Normalized Diluted EPS | -9.26 | -- | -- | -- | |
| Average Basic Shares Outstanding | 3.22M | -- | -- | -- | |
| Average Diluted Shares Outstanding | 3.22M | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |